Mirati Therapeutics, Inc. logo

Mirati Therapeutics, Inc. Share Price Today (NASDAQ: MRTX)

Mirati Therapeutics, Inc. share price is $0 & ₹0.00 as on 21 Jan 2024 IST

-58.7

(-100%)

Market is closed - opens 7 PM, 14 Jul 2025

Bell Icon

The stock has been delisted from the stock exchange on 22 Jan 2024

View live Mirati Therapeutics, Inc. share price in Dollar and Rupees. Guide to invest in Mirati Therapeutics, Inc. stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Mirati Therapeutics, Inc., along with analyst recommendations, forecasts, and comprehensive financials.

Mirati Therapeutics, Inc. (MRTX) Key Statistics

in dollars & INR

Previous Close
$58.7
Open
$58.86
Market Capitalization
$4.1B
Today's Volume
$21.0M
Revenue TTM
$38.2M
EBITDA
$-760.7M
Earnings Per Share (EPS)
$-12.18
Dividend Yield
0.0%
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-69.95%

How to invest in Mirati Therapeutics, Inc. Stock (MRTX) from India?

It is very easy for Indian residents to invest directly in Mirati Therapeutics, Inc. from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Mirati Therapeutics, Inc. stock in both Indian Rupees (INR) and US Dollars (USD). Search for Mirati Therapeutics, Inc. or MRTX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Mirati Therapeutics, Inc. or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Mirati Therapeutics, Inc. shares which would translate to null fractional shares of Mirati Therapeutics, Inc. as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India , including recognised companies like Mirati Therapeutics, Inc., in just a few clicks!

Global Institutional Holdings in Mirati Therapeutics, Inc.

  • RTW INVESTMENTS, LLC

    9.65%

  • venBio Select Advisor LLC

    9.50%

  • EcoR1 Capital, LLC

    8.19%

  • Vanguard Group Inc

    8.13%

  • BlackRock Inc

    5.05%

  • Wellington Management Company LLP

    4.73%

Analyst Recommendation on Mirati Therapeutics, Inc.

Rating
Trend

Hold

    47%Buy

    52%Hold

    0%Sell

Based on 23 Wall street analysts offering stock ratings for Mirati Therapeutics, Inc.(by analysts ranked 0 to 5 stars)

About Mirati Therapeutics, Inc.

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Organization
Mirati Therapeutics, Inc.
Employees
587
CEO
Mr. David D. Meek
Industry
Health Technology

Important FAQs about investing in MRTX Stock from India :

Can Indians buy Mirati Therapeutics, Inc. shares?

Yes, Indians can invest in the Mirati Therapeutics, Inc. (MRTX) from India.

With INDmoney, you can buy Mirati Therapeutics, Inc. at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Mirati Therapeutics, Inc. at zero transaction cost.

How can I buy Mirati Therapeutics, Inc. shares from India?

It is very easy to buy Mirati Therapeutics, Inc. from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Mirati Therapeutics, Inc. (MRTX) be purchased?

Yes, you can buy fractional shares of Mirati Therapeutics, Inc. with INDmoney app.

What are the documents required to start investing in Mirati Therapeutics, Inc. stocks?

To start investing in Mirati Therapeutics, Inc., You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What is today's market capitalisation of Mirati Therapeutics, Inc.?

Today's market capitalisation of Mirati Therapeutics, Inc. MRTX is 4.1B

Who is the Chief Executive Officer (CEO) of Mirati Therapeutics, Inc. ?

Mr. David D. Meek is the current Chief Executive Officer (CEO) of Mirati Therapeutics, Inc..